SCHEMBL9435964

SCHEMBL9435964

CCNC(=O)Nc1ccc(OC)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.72
SMN1; SMN2 Q16637 3/20 0.72
NPC1 O15118 3/20 0.72
MTNR1B P49286 1/20 0.71
SAE1 Q9UBE0 1/20 0.65
UBA2 Q9UBT2 1/20 0.65
PKM P14618 1/20 0.64
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
KDM4E B2RXH2 2/20 0.60
MAPT P10636 2/20 0.60
POLB P06746 1/20 0.59
FPR2 P25090 4/20 0.58
CASR P41180 1/20 0.58
CNR1 P21554 1/20 0.58
TP53 P04637 1/20 0.58
ESR2 Q92731 1/20 0.58
NOX1 Q9Y5S8 1/20 0.58
L3MBTL1 Q9Y468 2/20 0.58
HDAC1 Q13547 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11282040 0.92 RAB9A (0.66) RAB9ASMN1; SMN2NPC1MTNR1BSAE1
SCHEMBL23560422 0.87 MTNR1B (0.57) RAB9ANPC1MTNR1BMEN1KMT2A
SCHEMBL8577837 0.86 SMN1; SMN2 (0.68) RAB9ASMN1; SMN2NPC1MTNR1BSAE1
SCHEMBL5786396 0.85 MTNR1B (0.67) RAB9ASMN1; SMN2NPC1MTNR1BMEN1
SCHEMBL11092496 0.85 RAB9A (1.00) RAB9ASMN1; SMN2NPC1SAE1UBA2
SCHEMBL4588526 0.84 RAB9A (0.70) RAB9ASMN1; SMN2NPC1SAE1UBA2
SCHEMBL10598972 0.83 SMN1; SMN2 (0.64) RAB9ASMN1; SMN2NPC1SAE1UBA2
SCHEMBL20708118 0.83 SMN1; SMN2 (0.68) RAB9ASMN1; SMN2NPC1SAE1UBA2
SCHEMBL17782894 0.83 RAB9A (0.68) RAB9ASMN1; SMN2NPC1SAE1UBA2
SCHEMBL24590128 0.83 RAB9A (0.68) RAB9ASMN1; SMN2NPC1MTNR1BSAE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170290809-A1 ANTIVIRAL AGENTS AND USES THEREOF GRIFFITH UNIVERSITY (AU) 2017-10-12 US disclosed
US-7662910-B2 Inhibitors for the soluble epoxide hydrolase THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-02-16 US disclosed
US-7576117-B1 Cyclic amine CCR3 antagonist TEIJIN LIMITED (JP) 2009-08-18 US disclosed
US-5283362-A Reacting with an amine, terminating the reaction before the formation of by-product CHEMIE LINZ GESELLSCHAFT M.B.H. (AT) 1994-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170290809-A1 ANTIVIRAL AGENTS AND USES THEREOF RNASE1, ENTPD5, ACE RAB9A 1505/4885SMN1; SMN2 3429/4885NPC1 1326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.